Table 1 Patient characteristics in the APD, MAVERICC and TRIBE cohorts.
Characteristics | Total n = 558 | ANGIOPREDICT (chemo BEV) | MAVERICC (FOLFIRI BEV) | TRIBE (FOLFIRI BEV) | Chi-square test p-value |
|---|---|---|---|---|---|
Sex | 0.78 | ||||
Male | 343 | 108(60%) | 103(63%) | 132(61%) | |
Female | 215 | 72(40%) | 60(37%) | 83(39%) | |
Age | <0.001 | ||||
≤65 | 334 | 77(43%) | 101(62%) | 156(73%) | |
>65 | 220 | 99(55%) | 62(38%) | 59(27%) | |
Unknown | 4(2%) | ||||
Grade | NA | ||||
1,2 | 151(84%) | NA | NA | ||
3,4 | 17(10%) | NA | NA | ||
Unknown | 12(6%) | NA | NA | ||
T-staging | NA | ||||
2,3 | 138(77%) | NA | NA | ||
4 | 37(20%) | NA | NA | ||
Unknown | 5(3%) | NA | NA | ||
N-staging | NA | ||||
0 | 46(25%) | NA | NA | ||
1 | 63(35%) | NA | NA | ||
2 | 59(33%) | NA | NA | ||
X | 6(7%) | ||||
Center | NA | ||||
CAIRO | 105(58%) | NA | NA | ||
RCSI | 21(12%) | NA | NA | ||
UHEI | 41(23%) | NA | NA | ||
VUMC | 13(7%) | NA | NA | ||
Chemotherapy backbone | 0.042 | ||||
FP-based | 555 | 177(98%) | 163(100%) | 215(100%) | |
Non-FP | 3 | 3(2%) | 0(0%) | 0(0%) | |
BVZ Therapy Line | <0.001 | ||||
First | 539 | 161(89%) | 163(100%) | 215(100%) | |
Second | 12 | 12(6%) | 0(0%) | 0(0%) | |
Higher | 7 | 7(4%) | 0(0%) | 0(0%) | |
Primary tumor site | NA | ||||
Colon | 128(71%) | NA | NA | ||
Rectum | 52(29%) | NA | NA | ||
Primary tumor site | 0.005 | ||||
Right-sided | 120 | NA | 67(41%) | 53(25%) | |
Left-sided | 243 | NA | 96(59%) | 147(68%) | |
Unknown | 15 | NA | 0(0%) | 15(7%) | |
Performance status | <0.001 | ||||
ECOG 0 | 274 | NA | 97(60%) | 177(82%) | |
ECOG 1 | 103 | NA | 66(40%) | 37(17%) | |
Unknown | 1 | NA | 0(0%) | 1(1%) | |
Number of metastases | <0.001 | ||||
<2 | 198 | NA | 106(65%) | 92(43%) | |
≥2 | 180 | NA | 57(35%) | 123(57%) | |
Liver limited disease | NA | ||||
No | 150 | NA | NA | 150(70%) | |
Yes | 65 | NA | NA | 65(30%) | |
Primary tumor resected | <0.001 | ||||
No | 233 | NA | 153(94%) | 80(37%) | |
Yes | 145 | NA | 10(6%) | 135(63%) | |
Adjuvant chemotherapy | 1 | ||||
No | 331 | NA | 143(88%) | 188(87%) | |
Yes | 47 | NA | 20(12%) | 27(13%) | |
KRAS status | 0.10 | ||||
Wild-type | 87(48%) | 87(54%) | 88(41%) | ||
Mutant | 60(33%) | 56(34%) | 90(42%) | ||
Unknown | 33(18%) | 20(12%) | 37(17%) | ||
BRAF status | 0.14 | ||||
Wild-type | 153(85%) | NA | 168(78%) | ||
Mutant | 18(10%) | NA | 10(5%) | ||
Unknown | 46 | 9(5%) | NA | 37(17%) |
